Physician profile
Michell Lozano Chinga
NPI 1467803726
$1,496.61
in general payments reported to CMS, 2019-2025
15 companies · $429 in 2025
The $429 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $350 · 2024: $718 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,496.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $328.84 | 2023-2025 | Ruconest, Joenja |
| Csl Behring | $315.49 | 2023-2025 | Hizentra |
| Sobi, INC | $178.62 | 2023-2024 | |
| Horizon Therapeutics Plc | $164.33 | 2023 | Actimmune |
| Takeda Pharmaceuticals U.S.A., INC. | $157.33 | 2024-2025 | Cuvitru, Hyqvia |
| Amgen INC. | $84.79 | 2024-2025 | Actimmune |
| Astrazeneca Pharmaceuticals LP | $61.59 | 2025 | |
| Incyte Corporation | $46.14 | 2024-2025 | Opzelura |
| Glaxosmithkline, LLC. | $39.11 | 2025 | Nucala |
| Galderma Laboratories, L.P. | $26.01 | 2025 | Nemluvio |
| Greer Laboratories, INC. | $23.26 | 2025 | Palforzia |
| Aimmune Therapeutics, INC. | $23.03 | 2023 | |
| Genzyme Corporation | $18.09 | 2025 | |
| Gc Biopharma USA, INC. | $16.48 | 2025 | Alyglo |
| Novartis Pharmaceuticals Corporation | $13.50 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michell Lozano Chinga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.